Why Medical Cannabis Advocates Are Still Battling
January 31, 2020 | Geoffrey Marshall
Matthew Carr for Cannabiz Now! via Profit Trends
In 1996, Californians cast their ballots for Proposition 215. This legalized medical marijuana in the state.
Over the next handful of years, Alaska, Colorado, the District of Columbia, Hawaii, Maine, Nevada, Oregon and Washington followed suit.
And that momentum didn’t die down. Today, 33 states have legalized medical cannabis. Roughly 60% of Americans live in a state that allows legal access to medical marijuana.
But there’s still plenty of work to be done.
To discuss this, I’m joined today by Americans for Safe Access (ASA) interim director, Debbie Churgai.
For nearly two decades, the nonprofit has been a champion for patient rights and consumer safety, and has strived to remove cannabis as a Schedule I drug.
For the medical marijuana industry, the current infrastructure in the U.S. provides several challenges. And Churgai delves into the difficulties medical marijuana companies – and patients – face.
We explore marijuana’s role in fighting the opioid crisis, as well as the Food and Drug Administration’s view that more CBD research needs to be done.
She also explains why cannabis advocacy continues to be imperative, particularly in today’s rapidly changing world.
Medical marijuana is a segment of the market I think investors shouldn’t ignore. This interview tackles some of the obstacles the industry currently faces – you don’t want to miss this!
Here’s to high returns,